Solid Biosciences Inc. Proceeds from Issuance of Warrants
Solid Biosciences Inc. (SLDB) reported Proceeds from Issuance of Warrants of $10.65 million for the 12-month period ending 2019-12-31, per its 10-K filed 2022-03-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfWarrants · last filed 2022-03-14
- Solid Biosciences Inc. proceeds from issuance of warrants for the quarter ending 2019-12-31 was $0.00.
- Solid Biosciences Inc. proceeds from issuance of warrants for fiscal 2019 was $10.65M.
| Period end | Proceeds from Issuance of Warrants 3 month | Proceeds from Issuance of Warrants 9 month | Proceeds from Issuance of Warrants 12 month |
|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $10.65M 10-K · filed 2022-03-14 | |
| 2019-09-30 | $10.65M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |